Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.

Adicet Bio Inc.

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Adicet Bio, with a price target of $20.00. Roy covers the Healt...

JonesTrading Keeps Their Buy Rating on Adicet Bio (ACET)

Guggenheim analyst Yatin Suneja maintained a Buy rating on Adicet Bio yesterday and set a price target of $100.00. The company’s shares closed yest...

Guggenheim Keeps Their Buy Rating on Adicet Bio (ACET)

Adicet Bio Inc (ACET) has disclosed a new risk, in the Innovation / R&D category. Adicet Bio Inc. faces a significant risk that its clinical trials...

Clinical Trial Uncertainty Puts Adicet Bio’s Prula-cel Program and Financial Outlook at Risk

In a report released today, Robert Driscoll from Wedbush reiterated a Buy rating on Adicet Bio, with a price target of $25.00. According to TipRank...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ACET	$6.86	0.00%	239.60K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ACET	$6.86	0%	239.60K
3
4
5
6

ACET

ACET

Get Adicet Bio Inc. Data in Excel

Get Adicet Bio Inc. Data in Excel